References
- Bartsch W, Horst H ‐J, Becker H, Nehse G. Sex hormone binding globulin binding capacity, testosterone, 5α‐dihydrotestosterone, oestradiol and prolactin in plasma of patients with prostatic carcinoma under various types of hormonal treatment. Acta Endocrinol 1977; 8: 664
- Boyns A R, Cole E N, Phillips E A, Hillier S G, Cameron H D, Griffiths K, Shahmanesh M, Feneley R C L, Hartog M. Plasma prolactin, GH, LH, FSH, TSH and testosterone during treatment of prostatic carcinoma with oestrogens. Eur J Cancer 1974; 10: 445–449
- Byar D P. Treatment of prostatic cancer: studies by the Veterans Administration Cooperative Urological Research group. Bull NY Acad Med 1972; 48: 751–766
- Damber J ‐E, Janson P O. The effects of LH, adrenaline and noradrenaline on testicular blood flow and plasma testosterone concentrations in anaesthetized rats. Acta Endocrinol 1978; 88: 390–396
- Farnsworth W E. A direct effect of estrogens on pro‐static metabolism of testosterone. Invest Urol 1969; 6: 423–427
- Farnsworth W E, Slaunwhite W R, Jr, Sharma M, Oseko F, Brown J R, Gonder M J, Cartagena R. Interaction of prolactin and testosterone in the human prostate. Urol Res 1981; 9: 79–88
- Harper M E, Peeling W B, Cowley T, Brawnsey B G, Phillips M E A, Groom G, Fahmy D R, Griffiths K. Plasma steroid and protein hormone concentrations in patients with prostatic carcinoma, before and during oestrogen therapy. Acta Endocrinol 1976; 81: 409–426
- Hedlund P O, Gustavsson H, Sjogren S. Cardiovascular complications to treatment of prostate cancer with estramustine phosphate (Estracyt) or conventional estrogen. Sand J Urol Nephrol 1980; 55: 103–105, SUPPI
- Horrobin D F, Lloyd I J, Lipton A, Burstyn P G, Durkin N, Muiruri K L. Actions of prolactin on human renal function. Lancet 1971; 2: 352–354
- Hwang P, Guyda H, Friesen H. A radioimmunoassay for human prolactin, proc. Natl Acad sci 1971; 68: 1902–1906
- Jacobi G H, Sinterhauf K, Kurth K ‐H, Altwein J E. Testosterone metabolism in patients with advanced carcinoma of the prostate: A comparative in vivo study of the effect of oestrogen and anti‐prolactin. Urol Res 1978; 6: 159–165
- Jacobi G H, Sinterhauf K, Kurth K ‐H, Altwein J E. Bromocriptine and prostatic carcinoma: plasma kinetics, production and tissue uptake of 3H‐testosterone in vivo. J Urol 1978; 119: 240–243
- Jönsson G, Olsson A M, Luttrop W, Cekan Z, Purvis K, Diczfalusy E. Reatment of prostatic carcinoma with various types of estrogen derivatives. Vitam Horn 1975; 33: 351–376
- Midgley A R, Jr. Radioimmunoassay: a method for humar, chorionic gonadotrophin and human luteinizing hormone. Endocrinology 1966; 79: 10–18
- Morales A, Pujary B. The choice of estrogen preparations in the treatment of prostatic cancer. CMA Journal 1975; 113: 865–867
- Odell W D, Rayford P L, Ross G T. Simplified partially automated method for radioimmunoassay of human thyroid‐stimulating, growth, luteinizing and follicle stimulating hormones. J Lab Clin Med 1967; 70: 973–980
- Shanbhag V P, Södergård R, Carstensen H, Andertsson P Å. A new method for the determination of the binding capacity of testosterone estradiol‐binding globulin in human plasma. J Steroid Biochem 1973; 4: 537–550
- Siegel S. Nonparametric statistics for the behavioral science. McGraw‐Hill Kogakusha Ltd, Tokyo 1956
- Tomić R, Bergman B, Damber J ‐E. Testicular endocrine function after withdrawal of oestrogen treatment in patients with carcinoma of prostate. Br J Urol 1983; 55: 42–47
- Walsh P C. Physiological basis for hormonal therapy in carcinoma of the prostate. Urol Clin North Am 1975; 2: 125–140